Premium
Impact of ABO incompatibility on allogeneic peripheral blood progenitor cell transplantation after reduced intensity conditioning
Author(s) -
Canals Carmen,
MuñizDíaz Eduardo,
Martínez Clara,
Martino Rodrigo,
Moreno Imma,
Ramos Adelaida,
Arilla Marina,
Boto Neus,
Pastoret Concepción,
Remacha Angel,
Sierra Jorge,
Madoz Pedro
Publication year - 2004
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/j.1537-2995.2004.04106.x
Subject(s) - abo blood group system , medicine , hemolysis , pure red cell aplasia , transplantation , immunology , anemia
BACKGROUND: Most studies indicate that ABO incompatibility has no effect on the clinical outcome after allogeneic peripheral blood progenitor cell (PBPC) transplantation (allo‐PBPCT). However, it carries additional risks of hemolytic reactions, delayed red blood cell (RBC) engraftment, and pure red cell aplasia (PRCA). Data on these events after reduced intensity conditioning (RIC) regimens are limited, but recent studies have suggested a higher transplant‐related mortality (TRM) and morbidity in this setting. STUDY DESIGN AND METHODS: We investigated the impact of ABO‐matching on the outcome of 77 patients included in a prospective RIC allo‐PBPCT protocol, focusing on engraftment, transfusion requirements, graft‐versus‐host disease, TRM, and survival. RESULTS: There were 17 (22%) minor and 8 (10%) major ABO‐incompatible transplants. No graft failures were observed. After major ABO‐incompatible grafts, RBC engraftment was delayed, longer thrombocytopenia periods were documented, and transfusion requirements increased. A transient mild hemolysis occurred in 10 patients, 7 (41%) minor and 3 (37%) major ABO‐mismatched. A PRCA was observed in a O+ patient with a pretransplant anti‐Jk a , grafted from an A + Jk a + donor. Graft‐versus‐host disease, disease progression, and TRM were not affected by ABO matching. CONCLUSION: ABO incompatibility was not associated with clinically relevant hemolysis after the RIC protocol used and did not impair the clinical outcome. PRCA was only observed in one patient, with a non‐ABO RBC allo‐antibody.